Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA’s “Limited-Use” Approval Pathway Moves Forward Without Congressional Approval

This article was originally published in The Pink Sheet Daily

Executive Summary

The agency seeks input on which diseases, beyond drug-resistant infections, could benefit from rapid approval of therapies for subpopulations of patients; public hearing in February will ask how labeling should best express the limited indications.

You may also be interested in...



The Regulatory Pendulum Swings In Favor Of Antibiotics, But Will Investments Follow?

New incentives under the US government’s GAIN Act and FDA’s openness to faster development are helping put antibiotics back on investors’ radar screens, if not yet loosening their checkbooks.

Antibiotic Incentives: FDA’s Woodcock Says LPAD Could Be Better Than Exclusivity, But Questions Remain

Rep. Phil Gingrey, lead sponsor of the Generating Antibiotic Incentives Now Act, says industry still has questions about the proposed approval pathway for antibiotics treating life-threatening diseases, further clouding its prospects.

FDA Exploring Limited-Use Approvals For Antibiotics Based On Small Development Programs

The agency would like to have a “special medical use” category for drugs, such as antibiotics for bacteria resistant to current therapies, that could be approved based on small trials and whose labeling says they should not be prescribed off-label.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS074755

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel